DNLI - Denali Therapeutics proposes $250M stock offering; shares down 6% post market
- Denali Therapeutics ( NASDAQ: DNLI ) plans to sell $250M in common stock as part of an underwritten public offering.
- Shares are down ~6% in post-market trading.
- Goldman Sachs, J.P. Morgan, and Jefferies are acting as joint book-runners.
- Underwriters have a 30-day option to purchase up to an additional 15% of the shares of common stock offered.
- Seeking Alpha's Quant Rating views Denali ( DNLI ) as a hold with high marks for profitability and momentum .
For further details see:
Denali Therapeutics proposes $250M stock offering; shares down 6% post market